Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Human sdr5-fc recombinant fusion protein and its application as a medicine for treating reproductive system inflammation

A fusion protein, sdr5-fc technology, applied in the direction of animal/human protein, drug combination, immunoglobulin, etc., to achieve the effect of enhancing curative effect, excellent safety, and promoting recovery

Active Publication Date: 2021-07-23
SHENZHEN ZHONGKE AMSHENN MEDICINE CO LTD
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, whether sDR5 has a therapeutic effect on seminal vesiculitis, there is no report at home and abroad

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Human sdr5-fc recombinant fusion protein and its application as a medicine for treating reproductive system inflammation
  • Human sdr5-fc recombinant fusion protein and its application as a medicine for treating reproductive system inflammation
  • Human sdr5-fc recombinant fusion protein and its application as a medicine for treating reproductive system inflammation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1 Design and Recombination of Recombinant sDR5-Fc Expression Sequence

[0042] After long-term research and a large number of experiments, the inventor constructed a recombinant fusion protein, expressed it in CHO cells and purified it to obtain the protein. The soluble fragment of human DR5 was fused with the Fc fragment of human immunoglobulin IgG1 in various ways. The results of mass spectrometry analysis showed that the N-terminus of the target protein was unstable, and multiple amino acid cleavages would occur. Based on this, multiple amino acid sequences were designed and prepared. The soluble fragment of human death receptor 5 (SEQ ID No. 1-4) at the carboxyl end and the Fc fragment of human IgG1 at the carboxyl end (SEQ ID NO. 5). Among them, the protein amino acid sequence of SEQ ID NO.1 is the shortest, and the recombinant protein formed by SEQ ID NO.1 and SEQ ID NO.5 contains the lowest splicing isoform ratio, which is 1% at 37 degrees, while SEQ ID N...

Embodiment 2

[0068] Example 2: Human sDR5-Fc antibody fusion protein treats vesiculitis.

[0069] 20 C57BL / 6 male mice were equally divided into 2 groups (normal saline group and 9mg / kg fusion protein group SEQ ID NO.6), 10 mice in each group, and each mouse was injected with 15mg / kg concanavalin by tail vein (ConA), 1 hour later, the mice in each group were given physiological saline and 9 mg / kg fusion protein by tail vein injection respectively, and the administration volume was 10 ml / kg. ConA, normal saline and fusion protein group were continuously injected for 15 weeks, then the mice were sacrificed, and the seminal vesicles of the mice were observed. Compared with the normal saline group, the seminal vesicles of the mice in the 9mg / kg fusion protein group were obviously not congested, and the appearance was normal (see figure 2 ). Therefore, the mice in the normal saline group had a significantly high incidence of seminal vesiculitis, and the incidence of seminal vesiculitis in the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a human sDR5‑Fc recombinant fusion protein and its application in the preparation of medicine for treating reproductive system inflammation. Specifically, the present invention constructs a fusion protein of the soluble fragment of human DR5 and the Fc fragment of human IgG1, and the amino acid sequence of the soluble fragment of human DR5 is as SEQ ID NO.1, SEQ ID NO.2, SEQ ID No.3 or SEQ ID NO.3 or SEQ ID NO. As shown in ID No.4, the amino acid sequence of the Fc fragment of human IgG1 is shown in SEQ ID NO.5, or has the same sequence as SEQ ID NO.1, SEQ ID NO.2, SEQ ID No.3, SEQ ID No.4 or SEQ ID NO.5 is a recombinant fusion protein with more than 95% homology and the same function. The invention also discloses the application of the human sDR5‑Fc recombinant fusion protein in the preparation of medicines for treating or preventing inflammation. Wherein inflammation is selected from seminal vesiculitis, prostatitis, urethritis. The recombinant fusion protein of the invention has good stability and high biological activity, and can be used efficiently and safely for the treatment of reproductive system inflammation.

Description

technical field [0001] The invention relates to a fusion protein, in particular to a human sDR5-Fc recombinant fusion protein and its application as a medicine for treating seminal vesiculitis. Background technique [0002] The seminal vesicle is the organ that stores sperm and has a rich vascular layer. Since the seminal vesicle and prostate are closely adjacent to the urinary tract, rectum and other organs, it is easy to cause infection. The stimulation of inflammatory substances after infection will lead to edema and congestion of the seminal vesicle wall. When the patient ejaculates, the smooth muscle contracts violently, resulting in the rupture of small blood vessels and blood semen. When the ejaculatory duct is spread by inflammation, it will lead to the narrowing of the ampulla of the seminal vesicle ejaculatory duct and the opening of the ejaculatory duct, which will further aggravate the inflammatory response and contribute to the formation of stones. On the contra...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K19/00C12N15/62A61K38/17A61K39/395A61P15/00A61P13/08A61P13/02
CPCA61K38/00C07K14/705C07K2317/52A61K38/17A61K39/395A61P13/02A61P13/08A61P15/00C07K19/00C12N15/62
Inventor 万晓春陈倩张青梅夏蒙
Owner SHENZHEN ZHONGKE AMSHENN MEDICINE CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com